BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 14, 2009
View Archived Issues
Ocrelizumab Hits Endpoint in RA Trial; Safety Questions Remain
Roche subsidiary Genentech Inc. and Biogen Idec Inc. said their first Phase III trial with anti-CD20 antibody ocrelizumab achieved its primary endpoint of improving ACR20 scores in rheumatoid arthritis patients. (BioWorld Today)
Read More
Dendreon: $356M Sale to Make Provenge, Gear Up for Launch
Read More
Genentech Pact Kaput, SeaGen Revs Effort with Lead Candidate
Read More
MiR-206 Affecting Nerve-Muscle Connection to Slow Down ALS
Read More
Universal Vaccine: 'End-Game' Pursuit to Counter Flu Pandemic
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Bench Press
Read More